본문 바로가기
KERD
논문KCI 등재

Patent Foramen Ovale and Other Cardiopathies as Causes of Embolic Stroke With Unknown Source

Jong S. Kim
대한뇌졸중학회 (The Korean Stroke Society)|2024.09|대한뇌졸중영문학회지 (Journal of stroke)|제26권 제3호|pp. 349-359

3

조회

0

다운로드

0

인용

0

참고문헌

키워드

StrokeEmbolismPatent foramen ovaleAnticoagulationEmbolic stroke with unknown source
주제분류신경과학

초록

In patients with stroke caused by cardiac embolism, the responsible heart diseases include atrial fibrillation, acute myocardial infarction, sick sinus syndrome, valvular disease, and significant heart failure. When there is no clear source of the embolism, the condition is referred to as “embolic stroke with unknown source (ESUS).” Recent studies have shown that the most common cause of ESUS is a right-to-left cardiac shunt through a patent foramen ovale (PFO). However, considering that PFOs are found in up to 25% of the general population, their presence does not necessarily indicate causality. In patients with ESUS associated with a PFO, either anticoagulants or antiplatelets are used for the prevention of future strokes or transient ischemic attacks. However, it currently remains unclear which treatment is superior. Nevertheless, recent randomized clinical trials have shown that percutaneous closure of the PFO more effectively reduces the incidence of recurrent strokes compared to medical therapy alone in patients with PFO-related strokes. This benefit is especially significant when the PFO carries high-risk features, such as a large shunt or the presence of an atrial septal aneurysm. Furthermore, the effectiveness of PFO closure has been well documented in young patients (<60 years) with a high-risk PFO development. In other cases, the therapeutic decision should be made through discussion among neurologists, cardiologists, and patients. Notably, in ESUS patients without a PFO, the underlying heart condition itself may be the source of embolism, with left atrial enlargement being the most important factor. Theoretically, anticoagulants such as non-vitamin K antagonist oral anticoagulants (NOACs) would be an effective therapy in these cases. However, recent trials have failed to show that NOACs are superior to antiplatelets in preventing further strokes in these patients. This may be due to the still uncertain definition of emboligenic cardiopathy and the presence of other potential embolic sources, such as mild but emboligenic arterial diseases. Overall, further research is needed to elucidate the source of embolism and to determine an effective management strategy for patients with ESUS.

Abstract

In patients with stroke caused by cardiac embolism, the responsible heart diseases include atrial fibrillation, acute myocardial infarction, sick sinus syndrome, valvular disease, and significant heart failure. When there is no clear source of the embolism, the condition is referred to as “embolic stroke with unknown source (ESUS).” Recent studies have shown that the most common cause of ESUS is a right-to-left cardiac shunt through a patent foramen ovale (PFO). However, considering that PFOs are found in up to 25% of the general population, their presence does not necessarily indicate causality. In patients with ESUS associated with a PFO, either anticoagulants or antiplatelets are used for the prevention of future strokes or transient ischemic attacks. However, it currently remains unclear which treatment is superior. Nevertheless, recent randomized clinical trials have shown that percutaneous closure of the PFO more effectively reduces the incidence of recurrent strokes compared to medical therapy alone in patients with PFO-related strokes. This benefit is especially significant when the PFO carries high-risk features, such as a large shunt or the presence of an atrial septal aneurysm. Furthermore, the effectiveness of PFO closure has been well documented in young patients (<60 years) with a high-risk PFO development. In other cases, the therapeutic decision should be made through discussion among neurologists, cardiologists, and patients. Notably, in ESUS patients without a PFO, the underlying heart condition itself may be the source of embolism, with left atrial enlargement being the most important factor. Theoretically, anticoagulants such as non-vitamin K antagonist oral anticoagulants (NOACs) would be an effective therapy in these cases. However, recent trials have failed to show that NOACs are superior to antiplatelets in preventing further strokes in these patients. This may be due to the still uncertain definition of emboligenic cardiopathy and the presence of other potential embolic sources, such as mild but emboligenic arterial diseases. Overall, further research is needed to elucidate the source of embolism and to determine an effective management strategy for patients with ESUS.

참고문헌 (75)

  1. Fonseca AC, "Cryptogenic stroke", Eur J Neurol, 22, pp.618~623 (2015)
  2. Alsheikh-Ali AA, "Patent foramen ovale in cryptogenic stroke : incidental or pathogenic?", Stroke, 40, pp.2349~2355 (2009)
  3. Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
  4. Yang H, "Cardiac diagnostic work-up of ischaemic stroke", Eur Heart J, 39, pp.1851~1860 (2018)
  5. Bang OY, "Patent foramen ovale and stroke-current status", J Stroke, 17, pp.229~237 (2015)
  6. Overell JR, "Interatrial septal abnormalities and stroke : a meta-analysis of case-control studies", Neurology, 55, pp.1172~1179 (2000)
  7. De Castro S, "Morphological and functional characteristics of patent foramen ovale and their embolic implications", Stroke, 31, pp.2407~2413 (2000)
  8. Mas JL, "Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both", N Engl J Med, 345, pp.1740~1746 (2001)
  9. Falanga G, "How to understand patent foramen ovale clinical significance : part I", J Cardiovasc Echogr, 24, pp.114~121 (2014)
  10. Zoghbi WA, "Patent foramen ovale : going beyond the bubbles", J Am Coll Cardiol Img, 7, pp.251~253 (2014)
  11. Mojadidi MK, "Accuracy of transcranial Doppler for the diagnosis of intracardiac right-to-left shunt : a bivariate meta-analysis of prospective studies", JACC Cardiovasc Imaging, 7, pp.236~250 (2014)
  12. Sorensen SG, "Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices", J Interv Cardiol, 23, pp.575~580 (2010)
  13. Wöhrle J, "Closure of patent foramen ovale after cryptogenic stroke", Lancet, 368, pp.350~352 (2006)
  14. Katsanos AH, "Recurrent stroke and patent foramen ovale : a systematic review and meta-analysis", Stroke, 45, pp.3352~3359 (2014)
  15. Prefasi D, "The utility of the RoPE score in cryptogenic stroke patients ≤50years in predicting a stroke-related patent foramen ovale", Int J Stroke, 11, pp.NP7~NP8 (2016)
  16. Kim JS, "Patent foramen ovale closure : opportunity closed in old patients?", J Stroke, 23, pp.147~148 (2021)
  17. Patti G, "Meta-analysis of net long-term benefit of different therapeutic strategies in patients with cryptogenic stroke and patent foramen ovale", Am J Cardiol, 115, pp.837~843 (2015)
  18. Furlan AJ, "Closure or medical therapy for cryptogenic stroke with patent foramen ovale", N Engl J Med, 366, pp.991~999 (2012)
  19. Carroll JD, "Closure of patent foramen ovale versus medical therapy after cryptogenic stroke", N Engl J Med, 368, pp.1092~1100 (2013)
  20. Meier B, "Percutaneous closure of patent foramen ovale in cryptogenic embolism", N Engl J Med, 368, pp.1083~1091 (2013)
  21. Kent DM, "Device closure of patent foramen ovale after stroke : pooled analysis of completed randomized trials", J Am Coll Cardiol, 67, pp.907~917 (2016)
  22. Saver JL, "Long-term outcomes of patent foramen ovale closure or medical therapy after stroke", N Engl J Med, 377, pp.1022~1032 (2017)
  23. Søndergaard L, "Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke", N Engl J Med, 377, pp.1033~1042 (2017)
  24. Mas JL, "Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke", N Engl J Med, 377, pp.1011~1021 (2017)
  25. Ntaios G, "Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack : updated systematic review and meta-analysis", Stroke, 49, pp.412~418 (2018)
  26. Mas JL, "Association of atrial septal aneurysm and shunt size with stroke recurrence and benefit from patent foramen ovale closure", JAMA Neurol, 79, pp.1175~1179 (2022)
  27. Kent DM, "Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke", JAMA, 326, pp.2277~2286 (2021)
  28. Pristipino C, "European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism", Eur Heart J, 40, pp.3182~3195 (2019)
  29. Alperi A, "Transcatheter closure of patent foramen ovale in older patients with cryptogenic thromboembolic events", Circ Cardiovasc Interv, 15, pp.e011652~ (2022)
  30. Krishnamurthy Y, "Incidence and time course of atrial fibrillation following patent foramen ovale closure", Catheter Cardiovasc Interv, 100, pp.219~224 (2022)
  31. Badoz M, "Incidence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure : protocol for the prospective, observational PFO-AF study", BMJ Open, 13, pp.e074584~ (2023)
  32. Messé SR, "Practice advisory update summary : patent foramen ovale and secondary stroke prevention : report of the Guideline Subcommittee of the American Academy of Neurology", Neurology, 94, pp.876~885 (2020)
  33. Mazzucco S, "Prognosis of cryptogenic stroke with patent foramen ovale at older ages and implications for trials : a population-based study and systematic review", JAMA Neurol, 77, pp.1279~1287 (2020)
  34. Lee PH, "Cryptogenic stroke and high-risk patent foramen ovale : the DEFENSE-PFO trial", J Am Coll Cardiol, 71, pp.2335~2342 (2018)
  35. Kwon H, "Patent foramen ovale closure in old stroke patients : a subgroup analysis of the DEFENSE-PFO trial", J Stroke, 23, pp.289~292 (2021)
  36. Lee PH, "Device closure or antithrombotic therapy after cryptogenic stroke in elderly patients with a high-risk patent foramen ovale", J Stroke, 26, pp.242~251 (2024)
  37. Wang AY, "Patent foramen ovale closure in older patients with stroke : patient selection for trial feasibility", Neurology, 102, pp.e209388~ (2024)
  38. Kim JS, "Establishment of the heart and brain team for patent foramen ovale closure in stroke patients : an expert opinion", J Stroke, 24, pp.345~351 (2022)
  39. Stalikas N, "Prevalence of markers of atrial cardiomyopathy in embolic stroke of undetermined source : a systematic review", Eur J Intern Med, 99, pp.38~44 (2022)
  40. Jalini S, "Atrial cardiopathy in patients with embolic strokes of unknown source and other stroke etiologies", Neurology, 92, pp.e288~e294 (2019)
  41. Kamel H, "Relationship between left atrial volume and ischemic stroke subtype", Ann Clin Transl Neurol, 6, pp.1480~1486 (2019)
  42. Kamel H, "Atrial fibrillation and mechanisms of stroke : time for a new model", Stroke, 47, pp.895~900 (2016)
  43. Lee YK, "Atrial cardiopathy biomarkers and MRI-based infarct patterns in patients with embolic strokes of undetermined source", J Stroke Cerebrovasc Dis, 30, pp.105933~ (2021)
  44. Benjamin EJ, "Left atrial size and the risk of stroke and death. The Framingham Heart Study", Circulation, 92, pp.835~841 (1995)
  45. Tsang TS, "Prediction of cardiovascular outcomes with left atrial size : is volume superior to area or diameter?", J Am Coll Cardiol, 47, pp.1018~1023 (2006)
  46. Edwards JD, "Atrial cardiopathy in the absence of atrial fibrillation increases risk of ischemic stroke, incident atrial fibrillation, and mortality and improves stroke risk prediction", J Am Heart Assoc, 9, pp.e013227~ (2020)
  47. Lang RM, "Recommendations for chamber quantification : a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology", J Am Soc Echocardiogr, 18, pp.1440~1463 (2005)
  48. Overvad TF, "Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review", Thromb Haemost, 116, pp.206~219 (2016)
  49. Bakalli A, "Prevalence of left chamber cardiac thrombi in patients with dilated left ventricle at sinus rhythm : the role of transesophageal echocardiography", J Clin Ultrasound, 41, pp.38~45 (2013)
  50. Katayama T, "Factors contributing to left atrial enlargement in adults with normal left ventricular systolic function", J Cardiol, 55, pp.196~204 (2010)
  51. Arboix A, "Cardioembolic stroke : clinical features, specific cardiac disorders and prognosis", Curr Cardiol Rev, 6, pp.150~161 (2010)
  52. Ruwald MH, "Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes : results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy(MADIT-CRT)trial", Circulation, 130, pp.2278~2286 (2014)
  53. Vaziri SM, "Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study", Circulation, 89, pp.724~730 (1994)
  54. Tsang TS, "Left atrial volume : important risk marker of incident atrial fibrillation in 1655 older men and women", Mayo Clin Proc, 76, pp.467~475 (2001)
  55. Rizzo AC, "The role of atrial cardiopathy as a potential cause of embolic stroke of undetermined source", J Stroke, 26, pp.330~334 (2024)
  56. Healey JS, "Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation : secondary analysis of the NAVIGATE ESUS randomized clinical trial", JAMA Neurol, 76, pp.764~773 (2019)
  57. Geisler T, "Apixaban versus aspirin for embolic stroke of undetermined source", NEJM Evid, 3, pp.EVIDoa2300235~ (2024)
  58. Kamel H, "The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial : rationale and methods", Int J Stroke, 14, pp.207~214 (2019)
  59. Kamel H, "Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy : the ARCADIA randomized clinical trial", JAMA, 331, pp.573~581 (2024)
  60. Kamel H, "P-wave morphology and the risk of incident ischemic stroke in the multi-ethnic study of atherosclerosis", Stroke, 45, pp.2786~2788 (2014)
  61. Folsom AR, "Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke : the atherosclerosis risk in communities study", Stroke, 44, pp.961~967 (2013)
  62. Maheshwari A, "Left atrial mechanical dysfunction and the risk for ischemic stroke in people without prevalent atrial fibrillation or stroke : a prospective cohort study", Ann Intern Med, 176, pp.39~48 (2023)
  63. Veltkamp R, "Characteristics of recurrent ischemic stroke after embolic stroke of undetermined source : secondary analysis of a randomized clinical trial", JAMA Neurol, 77, pp.1233~1240 (2020)
  64. Ospel JM, "Prevalence of non-stenotic(<50%)carotid plaques in acute ischemic stroke and transient ischemic attack : a systematic review and meta-analysis", J Stroke Cerebrovasc Dis, 29, pp.105117~ (2020)
  65. Ospel JM, "Prevalence of ipsilateral nonstenotic carotid plaques on computed tomography angiography in embolic stroke of undetermined source", Stroke, 51, pp.1743~1749 (2020)
  66. Kamtchum-Tatuene J, "Carotid plaque with high-risk features in embolic stroke of undetermined source : systematic review and meta-analysis", Stroke, 51, pp.311~314 (2020)
  67. Sakai Y, "Vessel wall MR imaging of aortic arch, cervical carotid and intracranial arteries in patients with embolic stroke of undetermined source : a narrative review", Front Neurol, 13, pp.968390~ (2022)
  68. Tao L, "Atrial cardiopathy and non-stenotic intracranial complicated atherosclerotic plaque in patients with embolic stroke of undetermined source", J Neurol Neurosurg Psychiatry, 93, pp.351~359 (2022)
  69. Park HK, "Left ventricular diastolic dysfunction in ischemic stroke : functional and vascular outcomes", J Stroke, 18, pp.195~202 (2016)
  70. Kuznetsova T, "Prevalence of left ventricular diastolic dysfunction in a general population", Circ Heart Fail, 2, pp.105~112 (2009)
  71. Hays AG, "Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population", Stroke, 37, pp.1715~1719 (2006)
  72. Takasugi J, "Detection of left ventricular thrombus by cardiac magnetic resonance in embolic stroke of undetermined source", Stroke, 48, pp.2434~2440 (2017)
  73. Ramasamy S, "Association between left ventricular ejection fraction, wall motion abnormality, and embolic stroke of undetermined source", J Am Heart Assoc, 8, pp.e011593~ (2019)
  74. Choi JY, "Left ventricular wall motion abnormalities are associated with stroke recurrence", Neurology, 88, pp.586~594 (2017)
  75. Merkler AE, "Left ventricular dysfunction among patients with embolic stroke of undetermined source and the effect of rivaroxaban vs aspirin : a subgroup analysis of the NAVIGATE ESUS randomized clinical trial", JAMA Neurol, 78, pp.1454~1460 (2021)

관련 논문AI추천

Patent Foramen Ovale and Stroke–Current StatusJi Won Kim, Mi ji Lee, Oh Young Bang, Sookyung Ryoo, Suk Jae Kim대한뇌졸중학회 · 대한뇌졸중영문학회지2015 · 제17권 제3호Updates on Prevention of Cardioembolic Strokes김동억, Liping Liu, M. Edip Gurol, Mehmet Akif Topcuoglu대한뇌졸중학회 · 대한뇌졸중영문학회지2018 · 제20권 제2호Association of Left Atrial Enlargement with Cortical Infarction in Subjects with Patent Foramen Ovale황지원, Chang Hyo Yoon, Chin-Sang Chung, Gyeong-Moon Kim, Kwang Ho Lee, Mi ji Lee, Oh Young Bang, Sookyung Ryoo, Suk Jae Kim, Sung-Ji Park대한뇌졸중학회 · 대한뇌졸중영문학회지2016 · 제18권 제3호Cerebrovascular Events in Older Patients With Patent Foramen Ovale: Current Status and Future PerspectivesChamorro Angel, Farjat-Pasos Julio I., Houde Christine, Lanthier Sylvain, Mengi Siddhartha, Robichaud Mathieu, Rodés-Cabau Josep대한뇌졸중학회 · 대한뇌졸중영문학회지2023 · 제25권 제3호The Role of Atrial Cardiopathy as a Potential Cause of Embolic Stroke of Undetermined SourceAndrea Bonelli, Andrea Di Pietro, Angelo Cascio Rizzo, Antonella Moreo, Benedetta De Chiara, Cristina Motto, Elio Clemente Agostoni, Francesco Aruta, Ghil Schwarz, Martina Di Pietro대한뇌졸중학회 · 대한뇌졸중영문학회지2024 · 제26권 제2호Device Closure or Antithrombotic Therapy After Cryptogenic Stroke in Elderly Patients With a High-Risk Patent Foramen Ovale허란, 김영대, 김중선, 이상엽, Bum Joon Kim, Byung Joo Sun, Jae-Kwan Song, Jang-Whan Bae, Jeong Yoon Jang, Ji Sung Lee, Jong Shin Woo, Jong S. Kim, Jung-Won Suh, Jun Yup Kim, Kyusup Lee, Pil Hyung Lee, Soe Hee Ann, Soo Jeong, Sung Hyuk Heo, Sun U. Kwon대한뇌졸중학회 · 대한뇌졸중영문학회지2024 · 제26권 제2호

이 간행물의 다른 논문 (12건)

Ruptured Peripheral Cerebral Aneurysms Associated With Moyamoya Disease: A Systematic ReviewChao Fu, Yongquan Chang, Zheng Fengpp. 360-370Ethnic Differences in the Safety and Efficacy of Tenecteplase Versus Alteplase for Acute Ischemic Stroke: A Systematic Review and Meta-AnalysisTeddy Wu, William Kok-Fai Kong, Benjamin Yong Qiang Tan, Vijay Kumar Sharma, Ching-Hui Sia, Jin Hean Koh, Claire Yi Jia Lim, Lucas Tze Peng Tan, Kian Keong Poh, Leonard Leong Litt Yeo, Andrew Fu Wah Hopp. 371-390Carbonated Beverage, Fruit Drink, and Water Consumption and Risk of Acute Stroke: the INTERSTROKE Case-Control StudyFernando Lanas, Danuta Ryglewicz, Catriona Reddin, Annika Rosengren, Salim Yusuf, Martin O’Donnell, Xingyu Wang, Anna Czlonkowska, Andrew Smyth, Graeme J. Hankey, Albertino Damasceno, Helle Klingenberg Iversen, Shahram Oveisgharan, Fawaz Alhussain, Peter Langhorne, Dennis Xavier, Patricio Lopez Jaramillo, Aytekin Oguz, Clodagh McDermottpp. 391-402Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS TrialHui-Sheng Chen, Zhi-Guo Yao, Yu Cui, Jian Zhangpp. 403-414Early Improvement in Interstitial Fluid Flow in Patients With Severe Carotid Stenosis After Angioplasty and StentingShih-Pin Chen, Kai-Wei Yu, Te-Ming Lin, Chao-Bao Luo, Feng-Chi Chang, Jiing-Feng Lirng, Chih-Ping Chung, I-Hui Lee, Chia-Hung Wupp. 415-424
원문 보기